Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery

Anthropic has found its commercial moment, and it is a drugmaker's R&D department. On 16 September 2026, Novo Nordisk and Anthropic announced a collaboration under which the pharma company will use Anthropic's frontier models and test the 'Claude Science workbench' in 'specific research and development workflows'. Specific workflows, no less — a phrase built to survive legal review while committing to nothing. Every enterprise AI announcement of the last three years has been a 'collaboration' around a 'workbench' trialled in 'specific workflows', and not one of them has been obliged to say what happens on the day the workbench is confidently wrong.

Then comes Dario Amodei with the line the press release was clearly written around: the collaboration, he says, exists to give leading researchers access to frontier models, and AI's increasing capability could 'compress a century's worth of biological and medical breakthroughs into a decade'. A century into a decade — nobody ever pitches seventeen respectable years. Note the accounting convention: the upside is always denominated in centuries, while the accidents get settled individually, in small print, by whoever was in the trial arm that didn't work. And the decade will not shrink at the approval end, where the paperwork still moves at the speed of a fax machine.

Still, credit where it's due: pointing a frontier model at biology is a better use of the technology than most of what gets demoed. Anthropic, the lab that has spent years warning anyone with a microphone about the stakes, has landed a flagship customer whose pipeline economics hang on a handful of molecules and the patents quietly expiring beneath them — which is an honest commercial problem, unlike the ones being solved in chatbots. The catch is the phrase doing all the work: computational drug discovery has promised to compress that century before, and the century has proved remarkably elastic. If it does compress this time, we'll hear about it. If it doesn't, the 'specific workflows' will simply be retired, and nobody will be asked to explain which ones they were.